Top

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2 mutations in lung cancer, researchers at MD Anderson have now characterized HER2 mutation type and frequency across cancer types and found that poziotinib shows activity against the most common HER2 variants seen in cancer.

The study also reports results from a phase II clinical trial, in which...

HER2 protein structure showing the location of the drug binding pocket. Exon 19, 20 and 21 domains are colored in blue, pink and orange, respectively, with sites for common mutations labeled.

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Devon Carter

DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat cancers with existing defects in DNA repair, such as BRCA mutant cancers.

DDR inhibitors block critical DNA repair pathways that these cancers rely on to repair their DNA as they grow and divide. Other important DDR players being targeted by researchers are ataxia telangiectasia and Rad3-related...

illustration of damaged DNA

BY Scott Merville

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...

BY Scott Merville

After all 13 breast cancer patients in a first-of-its-kind clinical trial responded positively to a new targeted therapy, MD Anderson researchers...

BY Scott Merville

The largest analysis of metastatic melanoma patients who received a targeted therapy combination shows the treatment provides long-term survival...